Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pediatrix Medical GroupFRA:PDC +1.77%29 Cash-to-Debt is 0.65 as of Jun. 2026, which is 364% above its 10-year median of 0.14. GuruFocus rates FRA:PDC with a GF Score™ of 29/100 and a GF Value™ of €11.73 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 673 Healthcare Providers & Services companies, Pediatrix Medical Group ranks worse than 53.64% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pediatrix Medical Group's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.65.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Pediatrix Medical Groupcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Pediatrix Medical Group's Cash-to-Debt or its related term are showing as below:
FRA:PDC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.14 Max: 0.79
Current: 0.65
During the past 13 years, Pediatrix Medical Group's highest Cash to Debt Ratio was 0.79. The lowest was 0.02. And the median was 0.14.
FRA:PDC's Cash-to-Debt is ranked worse than 53.64% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: 0.78
vs FRA:PDC: 0.65
Pediatrix Medical Group (FRA:PDC) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Pediatrix Medical Group Cash-to-Debt Related Terms
Pediatrix Medical Group Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:PDC vs ADUS, GRDN, ASTH: Cash-to-Debt Comparison
For the Medical Care Facilities subindustry, Pediatrix Medical Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pediatrix Medical Group (FRA:PDC) has a Cash-to-Debt of 0.65 as of Jun. 2026. This is 364% above median its historical median of 0.14. Over the past decade, Pediatrix Medical Group's Cash-to-Debt has ranged from 0.02 to 0.79. According to the industry distribution chart, Pediatrix Medical Group ranks #361 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 53.6%.
Is Pediatrix Medical Group's Cash-to-Debt too high?
Pediatrix Medical Group's current Cash-to-Debt of 0.65 is 364% above median its 10-year median of 0.14. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.79. The Healthcare Providers & Services industry median Cash-to-Debt is 0.78. Pediatrix Medical Group's value of 0.65 is 16.7% below this industry median. Based on the distribution chart, Pediatrix Medical Group ranks #361 out of 673 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pediatrix Medical Group has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's Cash-to-Debt compare to ADUS and GRDN?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #361 out of 673 companies for Cash-to-Debt. This places Pediatrix Medical Group in the lower half of its industry. The industry median Cash-to-Debt is 0.78. Pediatrix Medical Group's value of 0.65 is 16.7% below this benchmark. Historically, Pediatrix Medical Group's own Cash-to-Debt has ranged from 0.02 to 0.79 over the past decade. While the company's 10-year median is 0.14 vs. the industry median of 0.78, Pediatrix Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.78, based on 673 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current Cash-to-Debt of 0.65 is 16.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current Cash-to-Debt is 0.65, which is 364% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Pediatrix Medical Group (FRA:PDC) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.73, compared to a current price of €23.00 — trading 96.1% above its estimated fair value. The current Cash-to-Debt is 0.65, which is 364% above median its 10-year median of 0.14 and 16.7% below the Healthcare Providers & Services industry median of 0.78. Pediatrix Medical Group's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current Cash-to-Debt is 0.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €23.00 is trading 96.1% above its estimated GF Value™ of €11.73.
GuruFocus considers Pediatrix Medical Group to be Significantly Overvalued.
Key valuation signals for FRA:PDC:
Cash-to-Debt: 0.65 (364% above median its 10-year median of 0.14)
GF Value™: €11.73 vs. price of €23.00 (96.1% above fair value)
Industry Position: 16.7% below the Healthcare Providers & Services median (#361 of 673)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
29GF Score
Get the complete analysis for FRA:PDC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
